# Neurotransmitters — Cofactors Master Reference

## Overview

This document provides a unified reference table for every vitamin, mineral, and cofactor involved in neurotransmitter **synthesis, activation, and degradation** across all major pathways. Use this alongside the individual neurotransmitter files for a complete picture.

---

## Master Synthesis Cofactor Table

| Vitamin / Mineral / Cofactor | Neurotransmitter Pathway Step | Enzyme | Consequence of Deficiency |
|---|---|---|---|
| **Vitamin B6 (PLP)** | Serotonin: 5-HTP → 5-HT | AADC | ↓ Serotonin |
| | Dopamine: L-DOPA → Dopamine | AADC | ↓ Dopamine, ↑ L-DOPA in neurons |
| | NE/EPI: L-DOPA → Dopamine (prerequisite) | AADC | ↓ NE, EPI |
| | GABA: Glutamate → GABA | GAD65/67 | ↓ GABA → seizure risk, anxiety |
| | GABA: GABA degradation | GABA-T | Dysregulated catabolism |
| | Histamine: Histidine → Histamine | HDC | ↓ Histamine synthesis |
| | Histamine: Gut degradation | DAO | ↓ DAO → histamine intolerance |
| **BH4 (Tetrahydrobiopterin)** | Serotonin: Tryptophan → 5-HTP | TPH1/TPH2 | Severe ↓ serotonin and dopamine |
| | Dopamine: Tyrosine → L-DOPA | Tyrosine hydroxylase (TH) | Severe ↓ dopamine; NE/EPI collapse |
| | NE/EPI: Tyrosine → L-DOPA (shared) | TH | Same collapse |
| **Folate (5-MTHF / B9)** | BH4 regeneration (→ serotonin, dopamine) | DHFR, DHPR | ↓ BH4 → ↓ 5-HT, DA |
| | SAM cycle → ASMT (melatonin) | MTR/MTHFR | ↓ Melatonin |
| | SAM cycle → COMT (catecholamine clearance) | COMT | Impaired catecholamine degradation |
| | SAM cycle → HNMT (histamine) | HNMT | Impaired CNS histamine clearance |
| **Vitamin B12 (Methylcobalamin)** | SAM regeneration (methionine synthase) | MTR | ↓ Melatonin; impaired COMT, HNMT |
| | Methyl-B12 → SAM → ASMT (melatonin NAS → melatonin) | ASMT | ↓ Melatonin |
| **Riboflavin (B2 / FAD)** | MAO-A degradation of serotonin, NE | MAO-A | Dysregulated monoamine catabolism |
| | MAO-B degradation of dopamine | MAO-B | Extended DA half-life |
| | BH4 synthesis (MTHFR needs FAD) | MTHFR | ↓ BH4 → ↓ serotonin, dopamine |
| | SAM cycle (MTRR needs FAD) | MTRR | SAM depletion |
| **Niacin (B3 / NAD⁺)** | Serotonin aldehyde → 5-HIAA | ALDH | Reduced terminal catabolism |
| | Dopamine aldehyde → DOPAC | ALDH | Dysregulated dopamine turnover |
| | Histamine aldehyde → imidazole acetaldehyde | ALDH | Minor histamine catabolism impairment |
| | GABA shunt: SSA → Succinate | SSADH | Elevated GABA; SSADH deficiency |
| | Glutamate synthesis (α-KG → Glu) | GDH | ↓ Glutamate synthesis |
| | Tryptophan competes with NAD⁺ synthesis | IDO/ACMSD | ↓ Serotonin (tryptophan diverted) |
| **Pantothenate (B5)** | Acetyl-CoA synthesis (→ ACh, → AANAT for melatonin) | PDH complex | ↓ ACh; ↓ Melatonin (NAS → NAS remains) |
| **Thiamine (B1)** | Pyruvate → Acetyl-CoA | PDH complex | ↓ ACh; ↓ GABA substrate (α-KG); Wernicke's |
| **Vitamin C (Ascorbate)** | NE: Dopamine → Norepinephrine | DBH | ↓ NE; excess DA |
| | BH4 stabilisation (antioxidant) | Nonenzymatic | Lower effective BH4 |
| | PAM (peptide C-terminal amidation) | PAM | ↓ Enkephalin potency; ↓ neuropeptide activity |
| | DAO upregulation (anti-inflammatory) | AOC1 gene expression | ↓ DAO → histamine intolerance |
| **Vitamin D** | TH gene expression (dopamine synthesis) | TH transcription | ↓ DA |
| | TPH2 gene expression (brain serotonin) | TPH2 transcription | ↓ Serotonin |
| **Iron (Fe²⁺)** | Serotonin: TPH1/TPH2 cofactor | TPH1/TPH2 | ↓ Serotonin; restless legs syndrome |
| | Dopamine: TH cofactor | TH | ↓ Dopamine → ADHD, RLS |
| | NE/EPI: TH cofactor (shared) | TH | ↓ NE, EPI |
| | Melatonin: TPH1 cofactor | TPH1 | ↓ Melatonin |
| **Copper (Cu²⁺)** | NE: Dopamine → Norepinephrine | DBH (active site metal) | ↓ NE (Menkes disease extreme) |
| | Histamine degradation (gut) | DAO (TPQ formation) | ↓ DAO → histamine intolerance |
| | Enkephalin amidation | PAM | ↓ Neuropeptide potency |
| **Zinc (Zn²⁺)** | Serotonin: AADC stabilisation | AADC | ↓ 5-HT |
| | Dopamine: AADC | AADC | ↓ DA |
| | GABA: GAD enzyme stability | GAD65/67 | ↓ GABA |
| | GABA-A receptor modulation | Allosteric | Reduced inhibitory tone |
| | Glutamate: NMDA allosteric inhibition | NMDA receptor | Increased excitotoxic risk |
| | Glutamate: GDH allosteric | GDH | ↓ Glutamate synthesis |
| | Enkephalin degradation | APN, NEP | Metalloprotease cofactor |
| | Prohormone processing (POMC, proenkephalin) | PC1, PC2 | Impaired opioid peptide cleavage |
| **Magnesium (Mg²⁺)** | NMDA receptor Mg²⁺-pore block | NMDA channel | Excitotoxicity |
| | COMT function | COMT | Impaired catecholamine clearance |
| | GS cofactor (glutamate → glutamine) | Glutamine synthetase | ↓ Glutamine → ↓ GABA and Glu supply |
| | SAM cycle (MAT cofactor) | MAT | ↓ SAM → ↓ ASMT, COMT, HNMT |
| **Calcium (Ca²⁺)** | Prohormone convertase activation | PC1, PC2 | ↓ β-Endorphin, enkephalin processing |
| | Vesicular exocytosis of all neurotransmitters | SNARE complex | Global NT release failure |
| **Manganese (Mn²⁺)** | Glutamine synthetase (astrocytes) | GS | ↓ Glutamine → ↓ GABA and Glu |
| **SAM** | Melatonin: NAS → Melatonin | ASMT | ↓ Melatonin; NAS accumulation |
| | Catecholamine inactivation | COMT | Excess DA, NE, EPI |
| | Histamine inactivation (CNS) | HNMT | Elevated CNS histamine |
| **DHA (Omega-3)** | 5-HT2A receptor density (serotonin) | Membrane effect | Reduced serotonin signalling |
| | D2 receptor density (dopamine) | Membrane effect | Altered dopaminergic tone |
| | NMDA receptor efficiency (glutamate) | Membrane effect | Reduced LTP |
| **Lipoic acid** | Acetyl-CoA synthesis → ACh | PDH complex | ↓ ACh |
| **Tryptophan** | Serotonin precursor | TPH1/TPH2 | ↓ Serotonin, Melatonin |
| **Tyrosine** | Dopamine, NE, EPI precursor | TH | ↓ All catecholamines |
| **Histidine** | Histamine precursor | HDC | ↓ Histamine |
| **Glutamate** | GABA precursor | GAD | ↓ GABA |
| **Choline** | Acetylcholine precursor (rate-limiting) | ChAT | ↓ ACh; memory impairment |
| **Methionine** | SAM precursor | MAT | ↓ Methylation capacity |

---

## Quick Reference: Which Nutrients Affect the Most Pathways

| Nutrient | Pathways Affected (count) | Primary Impact |
|---|---|---|
| **Vitamin B6 (PLP)** | Serotonin, Dopamine, NE/EPI, GABA, GABA-T, Histamine, DAO | 7 |
| **Folate (5-MTHF)** | BH4 regeneration (5-HT+DA), SAM (Melatonin, COMT, HNMT) | 5+ |
| **Vitamin B12** | SAM → ASMT, COMT, HNMT | 5 |
| **Riboflavin (B2 / FAD)** | MAO-A (5-HT+NE), MAO-B (DA), BH4, SAM cycle | 5 |
| **Iron (Fe²⁺)** | TPH (serotonin, melatonin), TH (DA, NE, EPI) | 5 |
| **Magnesium** | NMDA, COMT, GS, MAT (SAM) | 4 |
| **Zinc** | AADC (5-HT, DA), GAD (GABA), NMDA, GDH, enkephalins | 5+ |
| **Vitamin C** | DBH (NE), BH4 stability, PAM (neuropeptides), DAO | 4 |
| **Copper** | DBH (NE), DAO (histamine), PAM (neuropeptides) | 3 |
| **Niacin (B3 / NAD⁺)** | ALDH (5-HT, DA, NE catabolism), SSADH (GABA), GDH | 4 |

---

## Degradation Enzyme Cofactor Reference

| Enzyme | Neurotransmitter Catabolised | Cofactor Required |
|---|---|---|
| **MAO-A** | Serotonin, NE (primary), Dopamine | FAD (Riboflavin / B2) |
| **MAO-B** | Dopamine (primary), N-methylhistamine | FAD (Riboflavin / B2) |
| **COMT** | Dopamine, NE, EPI, catechol-oestrogens | SAM (B12, Folate, B2, Mg²⁺) |
| **HNMT** | Histamine (CNS/intracellular) | SAM (B12, Folate, B2, Mg²⁺) |
| **DAO (AOC1)** | Histamine (gut/plasma) | Cu²⁺, PLP (B6), NAD⁺ (B3) |
| **AChE** | Acetylcholine | None (serine esterase) |
| **BuChE** | Acetylcholine (backup), drugs | None |
| **GABA-T** | GABA | PLP (Vitamin B6) |
| **SSADH** | Succinic semialdehyde (GABA catabolism) | NAD⁺ (Niacin / B3) |
| **ALDH** | All monoamine aldehydes (5-HT, DA, NE intermediates) | NAD⁺ (Niacin / B3) |
| **NEP (neprilysin)** | Enkephalins, substance P, β-amyloid | Zn²⁺ |
| **APN (aminopeptidase N)** | Enkephalins (N-terminus) | Zn²⁺ |
| **Carboxypeptidase E** | β-Endorphin C-terminus | Zn²⁺ |

---

## BH4 (Tetrahydrobiopterin) — Detailed Reference

### What Is BH4?

BH4 is a **pteridine cofactor** synthesised endogenously from **GTP**. It is the essential electron donor for the aromatic amino acid hydroxylases — the rate-limiting enzymes in catecholamine and indoleamine synthesis — and for all three nitric oxide synthase (NOS) isoforms.

### Role in Neurotransmitter Synthesis

| Enzyme | Reaction | NT Produced |
|---|---|---|
| **Tryptophan hydroxylase (TPH1/2)** | Tryptophan → 5-HTP | Serotonin (→ Melatonin) |
| **Tyrosine hydroxylase (TH)** | Tyrosine → L-DOPA | Dopamine, NE, EPI |
| **Phenylalanine hydroxylase (PAH)** | Phenylalanine → Tyrosine | Precursor supply for TH step |
| **Nitric oxide synthase (eNOS, nNOS, iNOS)** | L-Arg → Nitric oxide | Vascular + neuronal signalling |

> **Note:** BH4 is consumed (oxidised to BH2) during each catalytic cycle and must be continuously regenerated.

### BH4 Synthesis Pathway

```
GTP
 │
 ▼  GCH1 (GTP cyclohydrolase 1) ← rate-limiting step
 │
7,8-Dihydroneopterin triphosphate
 │
 ▼  PTPS (6-pyruvoyltetrahydropterin synthase)
 │
6-Pyruvoyltetrahydropterin
 │
 ▼  SR (sepiapterin reductase) + NADPH
 │
BH4 ◄──────────────────── active cofactor
```

### BH4 Recycling Pathway

BH4 is oxidised to **quinonoid-BH2 (q-BH2)** during hydroxylase reactions, then recycled:

```
BH4 ──[TPH / TH / PAH]──► q-BH2 (quinonoid BH2)
                                │
                                ▼  DHPR (dihydropteridine reductase) + NADH
                               BH4  ◄── recycled

BH2 (oxidised, lost pool) ──► BH4  via  DHFR (dihydrofolate reductase) + NADPH
                                        ↑
                                   Requires active folate (5-MTHF / B9)
```

### Cofactors Required for BH4 Function

| Cofactor / Nutrient | Role |
|---|---|
| **GTP** | Primary substrate for BH4 de-novo synthesis (GCH1 step) |
| **NADPH** | Electron donor for sepiapterin reductase (SR) and DHFR |
| **NADH** | Electron donor for DHPR (recycling of q-BH2 → BH4) |
| **Folate (5-MTHF / B9)** | Required by DHFR to convert BH2 → BH4; MTHFR deficiency impairs this |
| **Riboflavin (B2 / FAD)** | MTHFR requires FAD; FAD depletion reduces folate-mediated BH4 recycling |
| **Vitamin C (Ascorbate)** | Protects BH4 from oxidative degradation; stabilises the active pool |
| **Iron (Fe²⁺)** | Non-haem iron is a cofactor for TPH and TH (alongside BH4) |

### What Depletes BH4?

| Factor | Mechanism |
|---|---|
| **Oxidative stress** | ROS oxidise BH4 directly → BH2 accumulation; uncouples NOS |
| **Folate / B9 deficiency** | Impairs DHFR-mediated BH2 → BH4 recycling |
| **B2 / FAD deficiency** | Reduces MTHFR activity → less 5-MTHF → less DHFR substrate |
| **MTHFR polymorphisms (C677T)** | Reduced MTHFR efficiency → folate insufficiency → ↓ BH4 recycling |
| **GCH1 mutations** | Rare; directly impairs de-novo BH4 synthesis (Dopa-responsive dystonia) |
| **Inflammation / cytokines** | Upregulate IDO (tryptophan → kynurenine), divert substrate away from serotonin; also promote BH4 oxidation |

### Clinical Consequences of BH4 Deficiency

| System | Effect |
|---|---|
| **Serotonin** | ↓ TPH activity → ↓ 5-HT → depression, anxiety, poor sleep |
| **Dopamine** | ↓ TH activity → ↓ L-DOPA → dopamine/NE/EPI collapse |
| **Nitric oxide** | NOS uncoupling → superoxide production instead of NO → endothelial dysfunction |
| **PKU** | BH4 deficiency (or unresponsiveness) → phenylalanine accumulation → neurotoxicity |
| **Dopa-responsive dystonia** | GCH1 mutations → severe BH4 deficiency → movement disorder responsive to L-DOPA |

### Therapeutic / Supplementation Notes

- **Sapropterin (Kuvan)** — synthetic BH4; FDA-approved for BH4-responsive PKU
- **Folate + B12** — first-line indirect support; ensure DHFR/MTHFR adequacy
- **Riboflavin (B2)** — improves folate recycling; especially important in MTHFR C677T carriers
- **Vitamin C** — antioxidant preservation of BH4 pool; 500–1000 mg/day commonly used adjunctively
- **NAC / Glutathione precursors** — reduce oxidative BH4 depletion
- **5-MTHF (methylfolate)** — bypasses MTHFR; preferred over folic acid when BH4 recycling is a concern

---

## Pathway Interaction Map

```
Tryptophan ──► Serotonin ──► Melatonin
                 ↑               ↑
               [B6, Fe, BH4]   [SAM, B12, B9, B2, B5]

Phenylalanine → Tyrosine ──► L-DOPA ──► Dopamine ──► NE ──► EPI
                  ↑              ↑          ↑        ↑      ↑
               [BH4, Fe]     [BH4, Fe]   [B6]  [Vit C, Cu] [SAM]

Histidine ──► Histamine ──► [HNMT: SAM] → CNS clearance
                          └──► [DAO: Cu, B6] → Gut clearance

Glutamate ──► [GAD: B6, Zn] ──► GABA ──► [GABA-T: B6] ──► Krebs
     ↑
[α-KG via Krebs: B1, B2, B3, lipoic acid]

Choline + Acetyl-CoA ──► [ChAT: B5→CoA] ──► ACh ──► [AChE] ──► Choline (recycled)

POMC/Proenkephalin ──► [PC1/PC2: Ca, Zn] ──► Endorphins/Enkephalins
                                          ──► [PAM: Vit C, Cu] ──► Amidated peptides
```

---

## Supplementation Strategy by Deficiency Pattern

| Clinical Picture | Suspected Deficiency | First-Line Support |
|---|---|---|
| Depression + fatigue + poor cold tolerance | Low serotonin + NE | B6, iron, folate, B12, Tryptophan |
| Anxiety + muscle tension + poor sleep | Low GABA + Mg | Mg glycinate, B6, zinc, L-theanine |
| Brain fog + poor memory | Low ACh | Choline (eggs, lecithin), B5, B1 |
| Low motivation + apathy | Low dopamine | Tyrosine, iron, B6, folate, Vit D |
| Histamine sensitivity + flushing | Low DAO | Copper, B6, Vit C; reduce alcohol |
| Delayed sleep onset | Low melatonin | Tryptophan, B6, B12, folate, light hygiene |
| Chronic pain + poor exercise tolerance | Low endorphins | Zinc, Vit C, protein, exercise |
| Restless legs + impulse control | Low DA (iron-related) | Iron assessment, Mg, B6 |
| Hypertension + anxiety + panic | Excess NE/EPI | Mg, relaxation; COMT support (B12, folate) |
| Low serotonin + low dopamine simultaneously | ↓ BH4 (upstream of both TPH & TH) | 5-MTHF, B2, Vit C, NAC; rule out MTHFR C677T |
